Methods and compositions for self-regulated release of active pharmaceutical ingredient

1. An abuse deterrent pharmaceutical composition comprising a unit dose, the unit dose comprising:

a particle portion, wherein the particle portion comprises:

a. a pharmaceutically active ingredient;

b. an acid soluble ingredient comprising a cationic copolymer based on methyl methacrylate; and

c. magnesium hydroxide; and

a pH modifying ingredient,

wherein the pH modifying ingredient is present in an amount sufficient to inhibit dissolution of the particle portion when three unit doses or greater of the abuse deterrent pharmaceutical composition is ingested, and

wherein the acid soluble ingredient and the pH modifying ingredient retard release of the pharmaceutically active ingredient when the three unit doses or greater of the composition is ingested.

2. The abuse deterrent pharmaceutical composition of claim 1 , wherein the pH modifying ingredient is present in an amount sufficient to raise the gastrointestinal pH to greater than about 4 when the three unit doses or greater of the abuse deterrent pharmaceutical composition is ingested.

3. The abuse deterrent pharmaceutical composition of claim 1 , wherein the pharmaceutically active ingredient comprises a drug susceptible to abuse.

4. The abuse deterrent pharmaceutical composition of claim 3 , wherein the drug susceptible to abuse comprises an opioid, a stimulant, and/or a sedative.

5. The abuse deterrent pharmaceutical composition of claim 4 , wherein the drug susceptible to abuse comprises an opioid selected from hydrocodone, hydromorphone, morphine, oxycodone, and/or salts thereof.

6. The abuse deterrent pharmaceutical composition of claim 1 , wherein the cationic copolymer is based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate.

7. The abuse deterrent pharmaceutical composition of claim 1 , further comprising a disintegrant.

8. The abuse deterrent pharmaceutical composition of claim 7 , wherein the disintegrant comprises sodium starch glycolate.

9. The abuse deterrent pharmaceutical composition of claim 1 , further comprising a lubricant.

10. The abuse deterrent pharmaceutical composition of claim 9 , wherein the lubricant comprises one or more of stearic acid, magnesium stearate, hydrogenated oil, sodium stearyl fumarate, and polyethylene glycol.

11. The abuse deterrent pharmaceutical composition of claim 1 , wherein the cationic copolymer is soluble in acid and insoluble above pH 5.

12. The abuse deterrent composition of claim 1 , wherein the unit dose is a capsule.

13. The abuse deterrent composition of claim 1 , wherein the unit dose is a tablet.

14. The abuse deterrent composition of claim 1 , wherein the acid soluble ingredient sequesters the pharmaceutically active ingredient from the pH modifying ingredient.

15. The abuse deterrent composition of claim 14 , wherein the acid soluble ingredient sequesters the pharmaceutically active ingredient from the pH modifying ingredient by coating the pharmaceutically active ingredient.

16. An abuse deterrent pharmaceutical composition comprising a unit dose, the unit dose comprising:

a particle portion, wherein the particle portion comprises:

a. a pharmaceutically active ingredient;

b. an acid soluble ingredient comprising one or more of calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, and magnesium hydroxide; and

c. a buffering ingredient; and

a pH modifying ingredient,

wherein the pH modifying ingredient is present in an amount sufficient to inhibit dissolution of the particle portion when three unit doses or greater of the abuse deterrent pharmaceutical composition is ingested, and

wherein the acid soluble ingredient and the pH modifying ingredient retard release of the pharmaceutically active ingredient when the three unit doses or greater of the composition is ingested.

17. The abuse deterrent pharmaceutical composition of claim 16 , wherein the pH modifying ingredient is present in an amount sufficient to raise the gastrointestinal pH to greater than about 4 when the three unit doses or greater of the abuse deterrent pharmaceutical composition is ingested.

18. The abuse deterrent pharmaceutical composition of claim 16 , wherein the pharmaceutically active ingredient comprises a drug susceptible to abuse.

19. The abuse deterrent pharmaceutical composition of claim 18 , wherein the drug susceptible to abuse comprises an opioid, a stimulant, and/or a sedative.

20. The abuse deterrent pharmaceutical composition of claim 19 , wherein the drug susceptible to abuse comprises an opioid selected from hydrocodone, hydromorphone, morphine, oxycodone, and/or salts thereof.

21. The abuse deterrent pharmaceutical composition of claim 16 , wherein the acid soluble ingredient and the pH modifying ingredient are the same ingredient.

22. The abuse deterrent pharmaceutical composition of claim 16 , wherein the pH modifying ingredient comprises one or more of aluminum hydroxide, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic sodium phosphate, dihydroxyaluminum aminoacetate, dihydroxyaluminum sodium carbonate, glycine, magnesium glycinate, magnesium hydroxide, magnesium oxide, potassium bicarbonate, sodium bicarbonate, sodium potassium tartrate, tricalcium phosphate, and magnesium hydroxide.

23. The abuse deterrent pharmaceutical composition of claim 16 , further comprising a disintegrant.

24. The abuse deterrent pharmaceutical composition of claim 23 , wherein the disintegrant comprises sodium starch glycolate.

25. The abuse deterrent pharmaceutical composition of claim 16 , further comprising a lubricant.

26. The abuse deterrent pharmaceutical composition of claim 25 , wherein the lubricant comprises one or more of stearic acid, magnesium stearate, hydrogenated oil, sodium stearyl fumarate, and polyethylene glycol.

27. The abuse deterrent pharmaceutical composition of claim 16 , further comprising a cationic copolymer comprising dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate.

28. The abuse deterrent pharmaceutical composition of claim 27 , wherein the cationic copolymer is soluble in acid and insoluble above pH 5.

29. The abuse deterrent pharmaceutical composition of claim 16 , wherein the unit dose is a capsule.

30. The abuse deterrent pharmaceutical composition of claim 16 , wherein the unit dose is a tablet.

31. The abuse deterrent pharmaceutical composition of claim 16 , wherein the acid soluble ingredient sequesters the pharmaceutically active ingredient from the pH modifying ingredient.

32. The abuse deterrent pharmaceutical composition of claim 31 , wherein the acid soluble ingredient sequesters the pharmaceutically active ingredient from the pH modifying ingredient by coating the pharmaceutically active ingredient.

33. The abuse deterrent pharmaceutical composition of claim 16 , wherein the particle portion is sequestered by from the pH modifying ingredient by a polymeric coating comprising a copolymer based on methyl methacrylate.

34. The abuse deterrent pharmaceutical composition of claim 16 , wherein the particle portion further comprises a cationic copolymer.

35. The abuse deterrent pharmaceutical composition of claim 34 , wherein the cationic copolymer comprises a methyl methacrylate copolymer.

36. An abuse deterrent pharmaceutical composition comprising an immediate release unit dose, the immediate release unit dose comprising:

a. a pharmaceutically active ingredient;

b. an acid soluble ingredient comprising a cationic polymer; and

c. a buffering ingredient,

wherein the buffering ingredient is in an amount sufficient to increase the gastric pH above 4 and the release of the active ingredient is retarded when at least 3 unit doses are ingested.

37. The abuse deterrent pharmaceutical composition of claim 36 , wherein the pharmaceutically active ingredient comprises a drug susceptible to abuse.

38. The abuse deterrent pharmaceutical composition of claim 37 , wherein the drug susceptible to abuse comprises an opioid, a stimulant, and/or a sedative.

39. The abuse deterrent pharmaceutical composition of claim 38 , wherein the drug susceptible to abuse comprises an opioid selected from hydrocodone, hydromorphone, morphine, oxycodone, and/or salts thereof.

40. The abuse deterrent pharmaceutical composition of claim 36 , wherein the cationic copolymer is based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate.

41. The abuse deterrent pharmaceutical composition of claim 36 , wherein the pH modifying ingredient comprises one or more of aluminum hydroxide, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic sodium phosphate, dihydroxyaluminum aminoacetate, dihydroxyaluminum sodium carbonate, glycine, magnesium glycinate, magnesium hydroxide, magnesium oxide, potassium bicarbonate, sodium bicarbonate, sodium potassium tartrate, tricalcium phosphate, and magnesium hydroxide.

42. The abuse deterrent pharmaceutical composition of claim 36 , further comprising a disintegrant.

43. The abuse deterrent pharmaceutical composition of claim 42 , wherein the disintegrant comprises sodium starch glycolate.

44. The abuse deterrent pharmaceutical composition of claim 36 , further comprising a lubricant.

45. The abuse deterrent pharmaceutical composition of claim 44 , wherein the lubricant comprises one or more of stearic acid, magnesium stearate, hydrogenated oil, sodium stearyl fumarate, and polyethylene glycol.

46. The abuse deterrent pharmaceutical composition of claim 36 , wherein the cationic copolymer is soluble in acid and insoluble above pH 5.